Search Results for:

Celltrion Expands Access to YUFLYMA (adalimumab-aaty)

On October 5, Celltrion Healthcare Co. announced that it has signed a contract with Ventegra, a major U.S. Medical Benefits Manager (MBM) “who administers pharmacy benefits through its Pharmacy Services Administration (PSA) model that has been effectively displacing traditional PBM’s.”  According to the press release, YUFLYMA (adalimumab-aaty) will be a…

Read More

Genentech Files Lawsuits Against Biogen and Millennium for Past Royalties on the Cabilly Patents

This week, Genentech filed separate lawsuits against Biogen and Millennium, alleging breach of a license agreement to the Cabilly patents (U.S. Patent No. 6,331,415 and 7,923,221).  The patents are generally directed to processes for producing an antibody or an antibody fragment by transforming a host cell with a first and…

Read More

Genentech BPCIA Trastuzumab Case Against Tanvex Dismissed After Settlement

As previously reported, Genentech and Tanvex reached an agreement in January 2022 to settle BPCIA litigation relating to Tanvex’s biosimilar of HERCEPTIN (trastuzumab).  On February 9, the court entered an order dismissing all claims in the case.  Tanvez’s trastuzumab biosimilar has not yet been approved by FDA. Genentech previously settled…

Read More

An Interview with Rachel Goode, Ph.D, about Biological Patent Thickets

Kevin DeJong (Senior Editor) and Shweta Kumar (Editor) from the Big Molecule Watch recently interviewed Rachel Goode, Ph.D. to discuss an article she recently co-authored, “Biological patent thickets and delayed access to biosimilars, an American problem.”[1]  The article, published in the Journal of Law and the Biosciences, examines whether patent…

Read More

Regeneron Identifies Six Patents for Expedited Trial in BPCIA Aflibercept Case Against Mylan

As we reported last week, the Northern District of West Virginia court has ordered an expedited trial in Regeneron’s aflibercept BPCIA case against Mylan.  As required by the court’s scheduling order, on October 28, Regeneron identified six patents for the first phase of the litigation.  Regeneron also agreed that “it will…

Read More